SpliceBio
Home - Splice Bio
Barcelona, Spain · Founded 2014 · $192.0M raised
- Headquarters
- Barcelona
- Employees
- 11–50
- Founded
- 2014
- Business Model
- B2C
- Website
- splice.bio
- Total Funding
- $192.0M
- Last Round
- $135.0M Series BJun 2025
- Rounds
- 3
About
SpliceBio is a clinical-stage genetic medicines company pioneering Protein Splicing to address diseases caused by mutations in large genes. Its platform, rooted in over 20 years of intein research at Princeton University, is advancing gene therapies including lead program SB-007 for Stargardt disease.
Summary
SpliceBio is a Biotech company based in Barcelona, Spain, founded in 2014. It has raised $192.0M in total across 3 rounds, most recently a $135.0M Series B round in Jun 2025. Investors include Ysios Capital, Sanofi Ventures and EQT AB.
Tech & App Stack
5 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Jun 2025
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Novel DNA sequencing architecture to scale the ultra low cost whole genome
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Global contract research organization providing comprehensive drug development and laboratory ser...